Sandra Horning - 28 Apr 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Director
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 28 Apr 2022
Net transactions value: $0
Form type: 4
Filing time: 02 May 2022, 16:38:59 UTC
Previous filing: 20 Dec 2021
Next filing: 03 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$0	+703		$0.000000	703	28 Apr 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-703	-100%	$0.000000^*	0	28 Apr 2022	Common Stock	703	$0.000000	Direct	F1, F2
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+4,061		$0.000000	4,061	28 Apr 2022	Common Stock	4,061	$142.52	Direct	F3
transaction	MRNA	Restricted Stock Units	Award	$0	+670		$0.000000	670	28 Apr 2022	Common Stock	670	$0.000000	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	The shares subject to this restricted stock unit award vested in full on April 28, 2022.
F3	This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F4	The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.